
Publicaciones
Investigación publicada de Orlando Immunology Center
Artículos científicos de los médicos de Orlando Immunology Center, según el índice de PubMed.
Cada entrada enlaza al artículo y a su registro en PubMed. Los autores de nuestro equipo aparecen en negrita y los títulos se muestran en su idioma original. Estos mismos médicos atienden pacientes en OIC Inspired, una clínica independiente en Orlando. Orlando Immunology Center es su centro de investigación clínica. OIC Inspired también publica una selección de estos artículos en su sitio web.
En muchos ensayos multicéntricos grandes nuestros médicos participaron como investigadores del sitio. Figuran en el grupo del estudio, no en la línea de autores. Esos artículos llevan la etiqueta "Investigador del sitio" y se pueden agregar con la casilla de arriba.
2026
- Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study
Markowitz M, Lalezari JP, DeJesus E, et al. Lancet HIV. 2026. PubMed
- Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study
Córdova E, Rolle CP, Hove K, et al. Open Forum Infect Dis. 2026. PubMed
- Patient-Reported Outcomes Among Virally Suppressed People Living with HIV Switching to Dolutegravir/Lamivudine vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide from the Randomized DYAD Study
Rolle CP, Castano J, Nguyen V, Hinestrosa F, DeJesus E AIDS Behav. 2026. PubMed
- Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Colson AE, Kumar PN, Ruane PJ, et al. Lancet. 2026. PubMed Investigador del sitio: Dr. DeJesus, Dr. Hinestrosa, Dra. Rolle
- Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment
Rockstroh JK, Ramgopal MN, Curran Fàbregas A, et al. N Engl J Med. 2026. PubMed Investigador del sitio: Dr. DeJesus, Dr. Hinestrosa, Dra. Rolle
- Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial
Theodore DA, Mayer BT, Rolle CP, DeJesus E, et al. Nat Med. 2026. PubMed
- Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile
Rogg L, Nuñez SA, Mingrone MV … Rolle CP, et al. Clin Infect Dis. 2026. PubMed
- Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Meissner EG, Ramgopal M, Ruane PJ … DeJesus E, et al. Lancet HIV. 2026. PubMed
- Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial
Martínez E, Watanabe M, Hoffman R, et al. Lancet HIV. 2026. PubMed Investigador del sitio: Dr. DeJesus
- Association of long COVID with health-related quality-of-life outcomes
Gandhi MM, Moser C, Currier JS, et al. Sci Rep. 2026. PubMed Investigador del sitio: Dr. DeJesus, Dra. Rolle
- Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study
Landovitz RJ, Pinedo Y, Hinestrosa F, et al. Clin Infect Dis. 2026. PubMed
- Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
Orkin C, Ruane PJ, Hedgcock M, et al. Lancet. 2026. PubMed Investigador del sitio: Dr. DeJesus
- Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
Colson AE, Mills AM, Ramgopal MN … Hinestrosa F, et al. Lancet. 2026. PubMed
- Evaluation of Mycoplasma genitalium positivity and co-infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae at various care sites across the United States
Lillis R, Arcenas R, Boraas CM … Hinestrosa F, et al. Int J Infect Dis. 2026. PubMed
- Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
Rolle C, Achhra A, Harbison C, et al. Clin Infect Dis. 2026. PubMed
2025
- Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I
Rolle CP, D'Antoni ML, Corales R, et al. AIDS Res Ther. 2025. PubMed
- Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location
Van Der Pol B, Arcenas R, Boraas C … Hinestrosa F, et al. J Clin Microbiol. 2025. PubMed
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
Leone PA, Ferro A, Rolle CP, et al. J Infect Dis. 2025. PubMed
- Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
Fichtenbaum CJ, Malvestutto CD, Watanabe MG, et al. Lancet HIV. 2025. PubMed Investigador del sitio: Dr. DeJesus
- Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials
Andrews LIB, Halloran ME, Neuzil KM, et al. JAMA Netw Open. 2025. PubMed Investigador del sitio: Dr. DeJesus, Dra. Rolle
- Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab
Eron JJ, Cook PP, Mehrotra ML … DeJesus E J Infect Dis. 2025. PubMed
- Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials
Rolle CP, Arribas JR, Ortiz R, et al. Open Forum Infect Dis. 2025. PubMed
- Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
Rockstroh JK, Paredes R, Cahn P … Hinestrosa F, et al. Clin Infect Dis. 2025. PubMed
- Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks
Rolle CP, Garrett J, Castano J … Hinestrosa F, DeJesus E Medicine (Baltimore). 2025. PubMed
- Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial
Gathe JC, Dejesus E, Ramgopal MN, Rolle CP, et al. J Acquir Immune Defic Syndr. 2025. PubMed
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. N Engl J Med. 2025. PubMed Investigador del sitio: Dr. DeJesus, Dra. Rolle
- Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis
Eron JJ, Ramgopal M, Osiyemi O … DeJesus E, et al. HIV Med. 2025. PubMed
2024
- Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
Rolle CP, Castano J, Nguyen V, Hinestrosa F, DeJesus E Open Forum Infect Dis. 2024. PubMed
- A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod
Riddler SA, Benson CA, Brinson C … DeJesus E, et al. Infect Dis Ther. 2024. PubMed
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Julg B, Walker-Sperling VEK, Wagh K … Rolle CP, DeJesus E, et al. Nat Med. 2024. PubMed
- Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
Evering TH, Moser C, Jilg N, et al. EClinicalMedicine. 2024. PubMed Investigador del sitio: Dr. DeJesus, Dra. Rolle
- Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals
DeJesus E, Towner WJ, Gathe JC, et al. J Acquir Immune Defic Syndr. 2024. PubMed
- SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials
Fisher LH, Kee JJ, Liu A, et al. JAMA Netw Open. 2024. PubMed Investigador del sitio: Dra. Rolle
- Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
Molina JM, Rizzardini G, Orrell C … Hinestrosa F, et al. Lancet HIV. 2024. PubMed
- HIV rebound in HIV controllers is associated with a specific fecal microbiome profile
Cai Y, Podlaha O, Deeks SG … DeJesus E, et al. Eur J Immunol. 2024. PubMed
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Eron JJ, Little SJ, Crofoot G … DeJesus E, et al. Lancet HIV. 2024. PubMed
- Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
Orkin C, Molina JM, Cahn P, et al. Lancet HIV. 2024. PubMed Investigador del sitio: Dr. DeJesus
2023
- Risk of COVID-19 after natural infection or vaccination
Rick AM, Laurens MB, Huang Y, et al. EBioMedicine. 2023. PubMed Investigador del sitio: Dra. Rolle
- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Grinspoon SK, Fitch KV, Zanni MV, et al. N Engl J Med. 2023. PubMed Investigador del sitio: Dr. DeJesus
- Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Ogbuagu O, Segal-Maurer S, Ratanasuwan W, et al. Lancet HIV. 2023. PubMed Investigador del sitio: Dr. DeJesus
- Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials
Theodore DA, Branche AR, Zhang L, et al. JAMA Netw Open. 2023. PubMed Investigador del sitio: Dra. Rolle
- Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic
Mathai R, Hinestrosa F, DeJesus E, Rolle CP J Investig Med. 2023. PubMed
- Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
Sax PE, Arribas JR, Orkin C … DeJesus E, et al. EClinicalMedicine. 2023. PubMed
- Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Evering TH, Chew KW, Giganti MJ, et al. Ann Intern Med. 2023. PubMed Investigador del sitio: Dr. DeJesus, Dra. Rolle
- Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
Rolle CP, Berhe M, Singh T, et al. Open Forum Infect Dis. 2023. PubMed
- Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting
Rolle CP, Castano J, Nguyen V … Hinestrosa F, DeJesus E Antivir Ther. 2023. PubMed
2022
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Maaske J, Sproule S, Falsey AR … Rolle CP, et al. Front Immunol. 2022. PubMed
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Julg B, Stephenson KE, Wagh K … Rolle CP … DeJesus E, et al. Nat Med. 2022. PubMed
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022. PubMed
- Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Gartland M, Cahn P, DeJesus E, et al. Antimicrob Agents Chemother. 2022. PubMed
- Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study
Sutton KC, De Vente J, Leblanc R, Dejesus E, et al. Open Forum Infect Dis. 2022. PubMed
- Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Sadoff J, Gray G, Vandebosch A, et al. N Engl J Med. 2022. PubMed Investigador del sitio: Dr. DeJesus
- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
O'Brien MP, Forleo-Neto E, Sarkar N, et al. JAMA. 2022. PubMed Investigador del sitio: Dr. DeJesus, Dr. Hinestrosa, Dra. Rolle
- From declining PrEP to PrEP initiation as "first nature" – what changes PrEP initiation decisions among young, Black MSM
Huang W, Lockard A, Kelley CF … Rolle CM, et al. AIDS Care. 2022. PubMed
2021
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Stephenson KE, Julg B, Tan CS … Rolle CP … DeJesus E, et al. Nat Med. 2021. PubMed
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Falsey AR, Sobieszczyk ME, Hirsch I … DeJesus E, et al. N Engl J Med. 2021. PubMed
- Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
Rolle CP, Nguyen V, Patel K … DeJesus E, Hinestrosa F Medicine (Baltimore). 2021. PubMed
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
O'Brien MP, Forleo-Neto E, Musser BJ, et al. N Engl J Med. 2021. PubMed Investigador del sitio: Dr. DeJesus, Dr. Hinestrosa, Dra. Rolle
- A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
Sulkowski MS, Moon JS, Sherman KE … Hinestrosa F, et al. Hepatology. 2021. PubMed
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Ogbuagu O, Ruane PJ, Podzamczer D, et al. Lancet HIV. 2021. PubMed Investigador del sitio: Dr. DeJesus
- The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
SenGupta D, Brinson C, DeJesus E, et al. Sci Transl Med. 2021. PubMed
- Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
Rolle CP, Berhe M, Singh T, et al. AIDS. 2021. PubMed
- Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
Molina JM, Yazdanpanah Y, Afani Saud A … DeJesus E, et al. Lancet HIV. 2021. PubMed
- Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
Rolle CP, Nguyen V, Hinestrosa F, DeJesus E AIDS Res Ther. 2021. PubMed
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff J, Gray G, Vandebosch A, et al. N Engl J Med. 2021. PubMed Investigador del sitio: Dr. DeJesus
- Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida
Keyes J, Crouse EC, DeJesus E, Rolle CP J Investig Med. 2021. PubMed
- Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Riddler SA, Para M, Benson CA … DeJesus E, et al. Clin Infect Dis. 2021. PubMed
2020
- Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting
Rolle CP, Nguyen V, Hinestrosa F, DeJesus E J Virus Erad. 2020. PubMed
- Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
Lataillade M, Lalezari JP, Kozal M … De Jesus E, et al. Lancet HIV. 2020. PubMed
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Mayer KH, Molina JM, Thompson MA … DeJesus E, et al. Lancet. 2020. PubMed
- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment
Rolle CP, Marquez O, Nguyen V, Hinestrosa F, DeJesus E Int J STD AIDS. 2020. PubMed
- Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
Fichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, et al. J Infect Dis. 2020. PubMed Investigador del sitio: Dr. DeJesus, Dra. Rolle
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Orkin C, DeJesus E, Sax PE, et al. Lancet HIV. 2020. PubMed
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Kozal M, Aberg J, Pialoux G … DeJesus E, et al. N Engl J Med. 2020. PubMed
- HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, et al. PLoS One. 2020. PubMed
- A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
DeJesus E, Harward S, Jewell RC, et al. Clin Infect Dis. 2020. PubMed
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
Molina JM, Squires K, Sax PE … DeJesus E, et al. Lancet HIV. 2020. PubMed
- Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
Lathouwers E, Wong EY, Brown K, et al. AIDS Res Hum Retroviruses. 2020. PubMed Investigador del sitio: Dr. DeJesus
- Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study
Serota DP, Rosenberg ES, Sullivan PS … Rolle CM, et al. Clin Infect Dis. 2020. PubMed
- Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis
Orkin C, Molina JM, Lombaard J, DeJesus E, et al. Clin Infect Dis. 2020. PubMed
2019
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
Kityo C, Hagins D, Koenig E … DeJesus E, et al. J Acquir Immune Defic Syndr. 2019. PubMed
- PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA
Rolle CP, Onwubiko U, Jo J, et al. AIDS Behav. 2019. PubMed
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
Huhn GD, Eron JJ, Girard PM … DeJesus E, et al. AIDS Res Ther. 2019. PubMed
- Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Li SS, Gilbert PB, Carpp LN … DeJesus E, et al. J Virol. 2019. PubMed
- Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
Wong A, Goldstein D, Mallolas J, DeJesus E, et al. J Acquir Immune Defic Syndr. 2019. PubMed
- Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
Lok AS, Sulkowski MS, Kort JJ … Hinestrosa F, et al. Gastroenterology. 2019. PubMed
- Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Eron JJ, Orkin C, Cunningham D, et al. Antiviral Res. 2019. PubMed Investigador del sitio: Dr. DeJesus
- Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults
DeJesus E, Saleh S, Cheng S, et al. Pulm Circ. 2019. PubMed
- Contrasting Self-Perceived Need and Guideline-Based Indication for HIV Pre-Exposure Prophylaxis Among Young, Black Men Who Have Sex with Men Offered Pre-Exposure Prophylaxis in Atlanta, Georgia
Lockard A, Rosenberg ES, Sullivan PS … Rolle CM, et al. AIDS Patient Care STDS. 2019. PubMed
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Cahn P, Madero JS, Arribas JR, et al. Lancet. 2019. PubMed Investigador del sitio: Dr. DeJesus
2018
- Antiretroviral switch studies do matter
Daar ES, Ruane P, DeJesus E, et al. Lancet HIV. 2018. PubMed
- Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials
Hagins D, Orkin C, Daar ES … DeJesus E, et al. HIV Med. 2018. PubMed
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Daar ES, DeJesus E, Ruane P, et al. Lancet HIV. 2018. PubMed
- Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
Sax PE, DeJesus E, Crofoot G, et al. AIDS. 2018. PubMed
- Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia
Serota DP, Rosenberg ES, Lockard AM, Rolle CM, et al. Clin Infect Dis. 2018. PubMed
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Molina JM, Squires K, Sax PE … DeJesus E, et al. Lancet HIV. 2018. PubMed
- Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Winston A, Post FA, DeJesus E, et al. Lancet HIV. 2018. PubMed
- Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
DeJesus E, Haas B, Segal-Maurer S, et al. AIDS Res Hum Retroviruses. 2018. PubMed
- Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
Fong Y, Shen X, Ashley VC … DeJesus E, et al. J Infect Dis. 2018. PubMed
- Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Orkin C, Molina JM, Negredo E, et al. Lancet HIV. 2018. PubMed Investigador del sitio: Dr. DeJesus
- Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA ≥1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials
Sax P, DeJesus E, Wohl D, et al. Antivir Ther. 2018. PubMed
- Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
Pett SL, Amin J, Horban A, et al. HIV Med. 2018. PubMed Investigador del sitio: Dr. DeJesus
2017
- Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Cahn P, Kaplan R, Sax PE, et al. Lancet HIV. 2017. PubMed Investigador del sitio: Dr. DeJesus
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax PE, Pozniak A, Montes ML … DeJesus E, et al. Lancet. 2017. PubMed
- Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Orrell C, Hagins DP, Belonosova E, et al. Lancet HIV. 2017. PubMed Investigador del sitio: Dr. DeJesus
- Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM
Rolle CP, Rosenberg ES, Siegler AJ, et al. J Acquir Immune Defic Syndr. 2017. PubMed
- Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia
Rolle CP, Rosenberg ES, Luisi N, et al. Int J STD AIDS. 2017. PubMed
- Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
Gane EJ, DeJesus E, Janczewska E, et al. BMC Infect Dis. 2017. PubMed
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Bourlière M, Gordon SC, Flamm SL, et al. N Engl J Med. 2017. PubMed Investigador del sitio: Dr. Hinestrosa
- Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
Arribas JR, DeJesus E, van Lunzen J, et al. HIV Clin Trials. 2017. PubMed
- Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen
Gane EJ, Shiffman ML, Etzkorn K … Hinestrosa F, et al. Hepatology. 2017. PubMed
- Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
Arribas JR, Thompson M, Sax PE … DeJesus E, et al. J Acquir Immune Defic Syndr. 2017. PubMed
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Orkin C, DeJesus E, Ramgopal M, et al. Lancet HIV. 2017. PubMed
- Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
DeJesus E, Ramgopal M, Crofoot G, et al. Lancet HIV. 2017. PubMed
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Sax PE, DeJesus E, Crofoot G, et al. Lancet HIV. 2017. PubMed
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults
Gallant JE, Thompson M, DeJesus E, et al. J Acquir Immune Defic Syndr. 2017. PubMed
- Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
Lackey P, Mills A, Carpio F … DeJesus E, et al. Clin Drug Investig. 2017. PubMed
2016
- Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials
Choi JY, Sungkanuparph S, Anekthananon T … DeJesus E, et al. Infect Chemother. 2016. PubMed
- Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Lawitz E, Reau N, Hinestrosa F, et al. Gastroenterology. 2016. PubMed
- HIV pre-exposure prophylaxis for women
Sheth AN, Rolle CP, Gandhi M J Virus Erad. 2016. PubMed
- Use of a Prospective Sex Diary to Study Anal Lubricant and Enema Use Among High Risk Men Who Have Sex With Men-Implications for Human Immunodeficiency Virus Prevention
Rolle CP, Bolton MD, Kelley CF Sex Transm Dis. 2016. PubMed
- Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Pett SL, Amin J, Horban A, et al. Clin Infect Dis. 2016. PubMed Investigador del sitio: Dr. DeJesus
- Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Gallant JE, Daar ES, Raffi F … DeJesus E, et al. Lancet HIV. 2016. PubMed
- The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial
Dinges W, Girard PM, Podzamczer D … DeJesus E, et al. Medicine (Baltimore). 2016. PubMed
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
Lawitz E, Matusow G, DeJesus E, et al. Hepatology. 2016. PubMed
- A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Thompson M, Saag M, DeJesus E, et al. AIDS. 2016. PubMed
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Mills A, Arribas JR, Andrade-Villanueva J … DeJesus E, et al. Lancet Infect Dis. 2016. PubMed
- Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Gastroenterology. 2016. PubMed Investigador del sitio: Dr. Hinestrosa
- Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients
Everson GT, Sims KD, Thuluvath PJ … Hinestrosa F, et al. Liver Int. 2016. PubMed
- The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir
Wohl DA, Bhatti L, Small CB … DeJesus E, et al. HIV Med. 2016. PubMed
2015
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster GR, Afdhal N, Roberts SK, et al. N Engl J Med. 2015. PubMed Investigador del sitio: Dr. Hinestrosa
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld JJ, Jacobson IM, Hézode C, et al. N Engl J Med. 2015. PubMed Investigador del sitio: Dr. Hinestrosa
- Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial
Everson GT, Towner WJ, Davis MN … Hinestrosa F, et al. Ann Intern Med. 2015. PubMed
- Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
Murray DD, Suzuki K, Law M, et al. PLoS One. 2015. PubMed Investigador del sitio: Dr. DeJesus
- Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
Lalezari JP, Latiff GH, Brinson C, et al. Lancet HIV. 2015. PubMed Investigador del sitio: Dr. DeJesus
- The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will
Beyrer C, Birx DL, Bekker LG, et al. Lancet. 2015. PubMed Investigador del sitio: Dr. DeJesus
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Naggie S, Cooper C, Saag M, et al. N Engl J Med. 2015. PubMed Investigador del sitio: Dr. Hinestrosa
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles DL, Ruane PJ, Sulkowski MS … Hinestrosa F, et al. N Engl J Med. 2015. PubMed
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. N Engl J Med. 2015. PubMed Investigador del sitio: Dr. DeJesus
- Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results
Gallant JE, Koenig E, Andrade-Villanueva JF … DeJesus E, et al. J Acquir Immune Defic Syndr. 2015. PubMed
- Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Poordad F, Sievert W, Mollison L, et al. JAMA. 2015. PubMed Investigador del sitio: Dr. Hinestrosa
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Sax PE, Wohl D, Yin MT … DeJesus E, et al. Lancet. 2015. PubMed
- Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study
Mocroft A, Lundgren JD, Ross M, et al. PLoS Med. 2015. PubMed Investigador del sitio: Dr. DeJesus
- Why START? Reflections that led to the conduct of this large long-term strategic HIV trial
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, et al. HIV Med. 2015. PubMed Investigador del sitio: Dr. DeJesus
- Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1
Matsushita S, Yoshimura K, Ramirez KP, et al. AIDS. 2015. PubMed Investigador del sitio: Dr. DeJesus
- The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects
Ruane PJ, Brinson C, Ramgopal M, et al. HIV Med. 2015. PubMed Investigador del sitio: Dr. DeJesus
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Sulkowski M, Hezode C, Gerstoft J … DeJesus E, et al. Lancet. 2015. PubMed
- Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study
Berkowitz EM, Moyle G, Stellbrink HJ, et al. J Infect Dis. 2015. PubMed Investigador del sitio: Dr. DeJesus
2014
- Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial
DeJesus E, Fätkenheuer G, Orrell C, et al. HIV Clin Trials. 2014. PubMed
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Lawitz E, Sulkowski MS, Ghalib R … DeJesus E, et al. Lancet. 2014. PubMed
- Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection
Sulkowski MS, Naggie S, Lalezari J, et al. JAMA. 2014. PubMed Investigador del sitio: Dr. Hinestrosa
- Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
Cooper DA, Heera J, Ive P … Dejesus E, et al. AIDS. 2014. PubMed
- Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation
Nordell AD, McKenna M, Borges ÁH, et al. J Am Heart Assoc. 2014. PubMed Investigador del sitio: Dr. DeJesus
- Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial
Wohl DA, Bhatti L, Small CB … DeJesus E, et al. PLoS One. 2014. PubMed
- Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy
Moyle G, Hardy H, Uy J … DeJesus E Antivir Ther. 2014. PubMed
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Afdhal N, Zeuzem S, Kwo P, et al. N Engl J Med. 2014. PubMed Investigador del sitio: Dr. Hinestrosa
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
Afdhal N, Reddy KR, Nelson DR, et al. N Engl J Med. 2014. PubMed Investigador del sitio: Dr. Hinestrosa
- Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Kowdley KV, Gordon SC, Reddy KR, et al. N Engl J Med. 2014. PubMed Investigador del sitio: Dr. Hinestrosa
- Factors associated with D-dimer levels in HIV-infected individuals
Borges AH, O'Connor JL, Phillips AN, et al. PLoS One. 2014. PubMed Investigador del sitio: Dr. DeJesus
- HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing
Ross LL, Horton J, Hasan S … DeJesus E, et al. PLoS One. 2014. PubMed
- Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
Castagna A, Maggiolo F, Penco G, et al. J Infect Dis. 2014. PubMed Investigador del sitio: Dr. DeJesus
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Sulkowski MS, Gardiner DF, Rodriguez-Torres M … Hinestrosa F, et al. N Engl J Med. 2014. PubMed
- A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results
Clumeck N, Molina JM, Henry K … DeJesus E, et al. J Acquir Immune Defic Syndr. 2014. PubMed
- A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results
Wohl DA, Cohen C, Gallant JE … Dejesus E, et al. J Acquir Immune Defic Syndr. 2014. PubMed
- Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)
Margolis DA, Eron JJ, DeJesus E, et al. Antivir Ther. 2014. PubMed
- Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing
Melikian GL, Rhee SY, Varghese V … Dejesus E, et al. J Antimicrob Chemother. 2014. PubMed
2013
- Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection
Walmsley SL, Antela A, Clumeck N, et al. N Engl J Med. 2013. PubMed Investigador del sitio: Dr. DeJesus
- Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens
Mills AM, Cohen C, Dejesus E, et al. HIV Clin Trials. 2013. PubMed
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
Hammer SM, Sobieszczyk ME, Janes H … DeJesus E, et al. N Engl J Med. 2013. PubMed
- Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
Stellbrink HJ, Reynes J, Lazzarin A, et al. AIDS. 2013. PubMed Investigador del sitio: Dr. DeJesus
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults
Ruane PJ, DeJesus E, Berger D, et al. J Acquir Immune Defic Syndr. 2013. PubMed
- Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Kumar P, DeJesus E, Huhn G, et al. BMC Infect Dis. 2013. PubMed
- Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants
Fuchs JD, Sobieszczyk ME, Madenwald T, et al. J Acquir Immune Defic Syndr. 2013. PubMed Investigador del sitio: Dr. DeJesus
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
Jacobson IM, Gordon SC, Kowdley KV, et al. N Engl J Med. 2013. PubMed Investigador del sitio: Dr. Hinestrosa
- Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results
Gallant JE, Koenig E, Andrade-Villanueva J … DeJesus E, et al. J Infect Dis. 2013. PubMed
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Lawitz E, Lalezari JP, Hassanein T … Dejesus E, et al. Lancet Infect Dis. 2013. PubMed
- Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study
Bjerk SM, Baker JV, Emery S, et al. PLoS One. 2013. PubMed Investigador del sitio: Dr. DeJesus
- IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C
Lalezari J, Box T, O'Riordan W … Dejesus E, et al. Antivir Ther. 2013. PubMed
- Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK
Rockstroh JK, DeJesus E, Lennox JL, et al. J Acquir Immune Defic Syndr. 2013. PubMed
- A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results
Zolopa A, Sax PE, DeJesus E, et al. J Acquir Immune Defic Syndr. 2013. PubMed
- SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen
Campo R, DeJesus E, Bredeek UF, et al. Clin Infect Dis. 2013. PubMed
- Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study
Squires KE, Bekker LG, Eron JJ, et al. AIDS Res Hum Retroviruses. 2013. PubMed Investigador del sitio: Dr. DeJesus
- A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Rockstroh JK, DeJesus E, Henry K, et al. J Acquir Immune Defic Syndr. 2013. PubMed
- Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
Eron JJ, Clotet B, Durant J, et al. J Infect Dis. 2013. PubMed Investigador del sitio: Dr. DeJesus
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
Rodriguez-Torres M, Lawitz E, Kowdley KV … Dejesus E, et al. J Hepatol. 2013. PubMed
- Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
Orkin C, DeJesus E, Khanlou H, et al. HIV Med. 2013. PubMed
2012
- ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
Squires KE, Young B, DeJesus E, et al. HIV Clin Trials. 2012. PubMed
- Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK
DeJesus E, Rockstroh JK, Lennox JL, et al. HIV Clin Trials. 2012. PubMed
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Sax PE, DeJesus E, Mills A, et al. Lancet. 2012. PubMed
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
DeJesus E, Rockstroh JK, Henry K, et al. Lancet. 2012. PubMed
- Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans
McLaren PJ, Ripke S, Pelak K, et al. Hum Mol Genet. 2012. PubMed Investigador del sitio: Dr. DeJesus
- A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results
Kozal MJ, Lupo S, DeJesus E, et al. HIV Clin Trials. 2012. PubMed
- A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy
Clifford DB, Simpson DM, Brown S, et al. J Acquir Immune Defic Syndr. 2012. PubMed Investigador del sitio: Dr. DeJesus
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Molina JM, Lamarca A, Andrade-Villanueva J, et al. Lancet Infect Dis. 2012. PubMed Investigador del sitio: Dr. DeJesus
2011
- 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial
Young B, Vanig T, DeJesus E, et al. HIV Clin Trials. 2011. PubMed
- A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients
Dejesus E, Mills A, Bhatti L, et al. Int J Clin Pract. 2011. PubMed
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Eron JJ, Rockstroh JK, Reynes J, et al. Lancet Infect Dis. 2011. PubMed Investigador del sitio: Dr. DeJesus
- Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK
Rockstroh JK, Lennox JL, Dejesus E, et al. Clin Infect Dis. 2011. PubMed
- Response-guided telaprevir combination treatment for hepatitis C virus infection
Sherman KE, Flamm SL, Afdhal NH, et al. N Engl J Med. 2011. PubMed Investigador del sitio: Dr. DeJesus
- Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients
Vrouenraets SM, Wit FW, Fernandez Garcia E … Dejesus E, et al. HIV Med. 2011. PubMed
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Min S, Sloan L, DeJesus E, et al. AIDS. 2011. PubMed
- Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients
Skiest DJ, Cohen C, Mounzer K … Dejesus E, et al. HIV Clin Trials. 2011. PubMed
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
Cohen C, Elion R, Ruane P … DeJesus E, et al. AIDS. 2011. PubMed
- Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects
Lalezari J, Gathe J, Brinson C … Dejesus E, et al. J Acquir Immune Defic Syndr. 2011. PubMed
2010
- Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
Rodriguez AE, Dejesus E, Williams V, et al. Open AIDS J. 2010. PubMed
- A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial
Young B, Vanig T, Dejesus E, et al. HIV Clin Trials. 2010. PubMed
- Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial
Cohen C, Dejesus E, Lamarca A, et al. HIV Clin Trials. 2010. PubMed
- The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
International HIV Controllers Study, Pereyra F, Jia X … DeJesus E, et al. Science. 2010. PubMed
- Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir
Elion R, Berger D, Richmond G … Dejesus E, et al. HIV Clin Trials. 2010. PubMed
- Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
DeJesus E, Lalezari JP, Osiyemi OO, et al. Antivir Ther. 2010. PubMed
- Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
Squires KE, Young B, Dejesus E, et al. AIDS. 2010. PubMed
- Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients
Squires KE, Young B, DeJesus E, et al. HIV Clin Trials. 2010. PubMed
- Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study
Malan N, Su J, Mancini M, et al. AIDS Care. 2010. PubMed Investigador del sitio: Dr. DeJesus
- Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Lennox JL, Dejesus E, Berger DS, et al. J Acquir Immune Defic Syndr. 2010. PubMed
- Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
Ross LL, Weinberg WG, DeJesus E, et al. AIDS Res Hum Retroviruses. 2010. PubMed
- Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF
Hodder SL, Mounzer K, Dejesus E, et al. AIDS Patient Care STDS. 2010. PubMed
- Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection
Cooper DA, Heera J, Goodrich J … Dejesus E, et al. J Infect Dis. 2010. PubMed
- Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Steigbigel RT, Cooper DA, Teppler H, et al. Clin Infect Dis. 2010. PubMed Investigador del sitio: Dr. DeJesus
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Eron JJ, Young B, Cooper DA … Dejesus E, et al. Lancet. 2010. PubMed
- Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial
Suleiman J, Zingman BS, Diaz RS … DeJesus E, et al. J Infect Dis. 2010. PubMed
- Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control
Ferreira MA, Mangino M, Brumme CJ, et al. Am J Hum Genet. 2010. PubMed Investigador del sitio: Dr. DeJesus
- Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
Ross LL, Rouse E, Gerondelis P, DeJesus E, et al. J Antimicrob Chemother. 2010. PubMed
- Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection
McHutchison J, Goodman Z, Patel K, et al. Gastroenterology. 2010. PubMed Investigador del sitio: Dr. DeJesus
2009
- Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks
Jayaweera D, Dejesus E, Nguyen KL, et al. HIV Clin Trials. 2009. PubMed
- Virologic and immunologic activity of PegIntron in HIV disease
Angel JB, Greaves W, Long J … DeJesus E AIDS. 2009. PubMed
- Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection
Rodger AJ, Fox Z, Lundgren JD, et al. J Infect Dis. 2009. PubMed Investigador del sitio: Dr. DeJesus
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Lennox JL, DeJesus E, Lazzarin A, et al. Lancet. 2009. PubMed
- Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)
Ross L, Elion R, Lanier R, Dejesus E, et al. AIDS Res Hum Retroviruses. 2009. PubMed
- Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use
Boyle BA, Cohen CJ, DeJesus E, et al. AIDS Read. 2009. PubMed
- A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
Kumar PN, Salvato P, LaMarca A, DeJesus E, et al. AIDS Res Ther. 2009. PubMed
- Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
Dejesus E, Young B, Morales-Ramirez JO, et al. J Acquir Immune Defic Syndr. 2009. PubMed
- Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Hicks CB, DeJesus E, Sloan LM, et al. AIDS Res Hum Retroviruses. 2009. PubMed
- Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, et al. Clin Infect Dis. 2009. PubMed Investigador del sitio: Dr. DeJesus
- Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting
Boyle BA, Cohen CJ, DeJesus E, et al. AIDS Read. 2009. PubMed
- Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)
Yeni P, Lamarca A, Berger D, et al. HIV Med. 2009. PubMed Investigador del sitio: Dr. DeJesus
- Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1
Moyle G, DeJesus E, Boffito M, et al. Clin Infect Dis. 2009. PubMed
- Interruption of antiretroviral therapy is associated with increased plasma cystatin C
Mocroft A, Wyatt C, Szczech L, et al. AIDS. 2009. PubMed Investigador del sitio: Dr. DeJesus
- Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, et al. Antimicrob Agents Chemother. 2009. PubMed
2008
- Antiretroviral treatment update from the 17th International AIDS Conference
Boyle B, Cohen C, DeJesus E, et al. AIDS Read. 2008. PubMed
- Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, et al. AIDS. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
Fox Z, Phillips A, Cohen C, et al. AIDS. 2008. PubMed Investigador del sitio: Dr. DeJesus
- The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients
Gallant JE, Winston JA, DeJesus E, et al. AIDS. 2008. PubMed
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
Fätkenheuer G, Nelson M, Lazzarin A, et al. N Engl J Med. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Maraviroc for previously treated patients with R5 HIV-1 infection
Gulick RM, Lalezari J, Goodrich J … DeJesus E, et al. N Engl J Med. 2008. PubMed
- Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study
DeJesus E, Gottlieb MS, Gathe JC, et al. Antimicrob Agents Chemother. 2008. PubMed
- Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
SMART Study Group, El-Sadr WM, Grund B, et al. Ann Intern Med. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Molina JM, Andrade-Villanueva J, Echevarria J, et al. Lancet. 2008. PubMed Investigador del sitio: Dr. DeJesus
- First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America
Young B, Squires K, Patel P, Dejesus E, et al. AIDS. 2008. PubMed
- Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
Cooper DA, Steigbigel RT, Gatell JM, et al. N Engl J Med. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Raltegravir with optimized background therapy for resistant HIV-1 infection
Steigbigel RT, Cooper DA, Kumar PN, et al. N Engl J Med. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Ortiz R, Dejesus E, Khanlou H, et al. AIDS. 2008. PubMed
- Update on antiretroviral therapy: the 15th CROI
Boyle BA, Cohen CJ, DeJesus E, et al. AIDS Read. 2008. PubMed
- Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study
Elion R, Dejesus E, Sension M, et al. HIV Clin Trials. 2008. PubMed
- Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, et al. J Infect Dis. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, et al. J Infect Dis. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
DeJesus E, Ruane P, McDonald C, et al. HIV Clin Trials. 2008. PubMed
- High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients
Saag M, Balu R, Phillips E, et al. Clin Infect Dis. 2008. PubMed Investigador del sitio: Dr. DeJesus
- Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Smith KY, Weinberg WG, DeJesus E, et al. AIDS Res Ther. 2008. PubMed
- Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
Lalezari J, Yadavalli GK, Para M … Dejesus E, et al. J Infect Dis. 2008. PubMed
- Adherence to enfuvirtide and its impact on treatment efficacy
Rockstroh J, Dejesus E, Donatacci L, et al. AIDS Res Hum Retroviruses. 2008. PubMed
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
Arribas JR, Pozniak AL, Gallant JE, Dejesus E, et al. J Acquir Immune Defic Syndr. 2008. PubMed
2007
- Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
Boyle BA, Elion R, Cohen CJ, DeJesus E, et al. AIDS Read. 2007. PubMed
- Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients
DeJesus E, Rodwick BM, Bowers D, et al. J Int Assoc Physicians AIDS Care (Chic). 2007. PubMed
2006
- Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study
Elion R, Cohen C, DeJesus E, et al. HIV Clin Trials. 2006. PubMed
- Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection
Ruane P, Lang J, DeJesus E, et al. HIV Clin Trials. 2006. PubMed
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes–a 96-week analysis
Pozniak AL, Gallant JE, DeJesus E, et al. J Acquir Immune Defic Syndr. 2006. PubMed
- Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
DeJesus E, Piliero PJ, Summers K, et al. Antimicrob Agents Chemother. 2006. PubMed
- Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
DeJesus E, Berger D, Markowitz M, et al. J Acquir Immune Defic Syndr. 2006. PubMed
- The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Eron J, Yeni P, Gathe J … DeJesus E, et al. Lancet. 2006. PubMed
- Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
Gathe JC, Wood R, Sanne I, DeJesus E, et al. Clin Ther. 2006. PubMed
- Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
Youle M, Staszweski S, Clotet B … Dejesus E, et al. HIV Clin Trials. 2006. PubMed
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
Johnson M, Grinsztejn B, Rodriguez C … DeJesus E, et al. AIDS. 2006. PubMed
- Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
Thompson M, DeJesus E, Richmond G, et al. AIDS. 2006. PubMed
- Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
Gallant JE, DeJesus E, Arribas JR, et al. N Engl J Med. 2006. PubMed
2005
- Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)
Sosa N, Hill-Zabala C, Dejesus E, et al. J Acquir Immune Defic Syndr. 2005. PubMed
- Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial
Sulkowski MS, Dieterich DT, Bini EJ … Dejesus E, et al. J Acquir Immune Defic Syndr. 2005. PubMed
- Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
Markowitz M, Hill-Zabala C, Lang J, DeJesus E, et al. J Acquir Immune Defic Syndr. 2005. PubMed
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
Johnson M, Grinsztejn B, Rodriguez C … DeJesus E, et al. AIDS. 2005. PubMed
- Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study
Moyle GJ, DeJesus E, Cahn P, et al. J Acquir Immune Defic Syndr. 2005. PubMed
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
Johnson M, Grinsztejn B, Rodriguez C … DeJesus E, et al. AIDS. 2005. PubMed
- Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
Keiser PH, Sension MG, DeJesus E, et al. BMC Infect Dis. 2005. PubMed
2004
- Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
DeJesus E, Herrera G, Teofilo E, et al. Clin Infect Dis. 2004. PubMed
- New nucleoside/nucleotide backbone options: a review of recent studies
Ruane PJ, DeJesus E J Acquir Immune Defic Syndr. 2004. PubMed
- Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
DeJesus E, McCarty D, Farthing CF, et al. Clin Infect Dis. 2004. PubMed
- Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, et al. JAMA. 2004. PubMed
- SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
Gathe JC, Ive P, Wood R … DeJesus E, et al. AIDS. 2004. PubMed
- Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus
Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacotherapy. 2004. PubMed
- Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus
Dore GJ, Cooper DA, Pozniak AL, DeJesus E, et al. J Infect Dis. 2004. PubMed
- Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
Kuritzkes DR, Jacobson J, Powderly WG … DeJesus E, et al. J Infect Dis. 2004. PubMed
2003
- A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults
Lalezari JP, DeJesus E, Northfelt DW, et al. Antivir Ther. 2003. PubMed
- Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects
DeJesus E, Wald A, Warren T, et al. J Infect Dis. 2003. PubMed
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
Lalezari JP, Eron JJ, Carlson M … DeJesus E, et al. AIDS. 2003. PubMed
2002
- Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients
Sension MG, Bellos NC, Johnson J … DeJesus E, et al. HIV Clin Trials. 2002. PubMed
Ningún artículo coincide con la búsqueda.
Fuente: PubMed, Biblioteca Nacional de Medicina de EE. UU. Lista compilada el 19 de noviembre de 2026. Los productos en investigación que se nombran en estos artículos no están aprobados salvo que la FDA lo indique.
¿Quieres participar en un estudio?
Orlando Immunology Center tiene ensayos clínicos con reclutamiento abierto en tratamiento y prevención del VIH y otras enfermedades infecciosas. Las visitas, los laboratorios y el medicamento del estudio no tienen costo para los participantes.
Clinical Research